Mainz Biomed Announces New Collaboration

Mainz Biomed Announces New Collaboration Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. ColoAlert®, Mainz Biomed’s flagship product, is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer. The Instituto de Microecologia has been a pioneer in microbiota studies and food sensitivity for more than 60 years, focused on raise awareness about the importance of intestinal health through microbiological analysis and diagnosis of microbiota profiles and specific health parameters. Entering the market and beginning commercialization in Spain and Portugal mark the continued expansion of Mainz Biomed’s impact in Europe. “As we continue to form partnerships with third-party diagnostic labs such as the Instituto de Microecologia for test kit processing, our aim is to increase consumer access to affordable and reliable CRC screening tests like ColoAlert,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Early screening has the potential to dramatically impact the treatment and prevention of this deadly disease, as well as save lives.” Widely known across Spain for its pioneering work in intestinal health, The Instituto de Microecologia offers a wide range of diagnostic and analytical services and is continuously advancing its scientific and technical capabilities through ongoing internal research alongside external collaborations. The Institute employs the most innovative diagnostic techniques by continuously auditing procedures to ensure delivery of the highest standard of quality and reliability of diagnostic results. Source